C4 Therapeutics, Inc. CCCC
Set alert
3.37 USD +0.07 +2.12%
At close · Oct 30
3.28 -0.09 -2.77%
After hours · Oct 30, 4:41 PM ET
3.21 Day range 3.38
1.71 52-week range 4.67
- YTD
- +76.44%
- 1 year
- +36.99%
- Open
- 3.23
- Prev close
- 3.30
- Mkt cap
- 414.59M
- Vol
- 2.35M
- Avg vol
- 2.42M
- EPS
- -0.91
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.21
- High
- 3.38
- Forward P/E
- -2.37
- Beta
- 3.06
- Short ratio
- 7.10
- Inst. own
- 91.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 1, 2024
- 50-d avg
- 5.06
- 200-d avg
- 5.96
- 1y target
- 15.00
1Y chart
Signals (55)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 29, 2026 | 3 days ago |
| SMA: Bullish | Oct 28, 2026 | 4 days ago |
| SMA: Bullish | Oct 27, 2026 | 5 days ago |
| MACD: Buy Signal | Oct 19, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 12, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 2, 2026 | 1 month ago |
| SMA: Bullish | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Jul 15, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 6, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 24, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 8, 2026 | 4 months ago |
| RSI: Overbought | May 29, 2026 | 5 months ago |
| RSI: Overbought | May 13, 2026 | 5 months ago |
| MACD: Buy Signal | May 7, 2026 | 5 months ago |
| SMA: Bullish | Apr 30, 2026 | 6 months ago |
| SMA: Bearish | Apr 29, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 27, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 15, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 10, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 8, 2026 | 6 months ago |
| SMA: Bullish | Mar 31, 2026 | 7 months ago |
| SMA: Bearish | Mar 30, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 13, 2026 | 7 months ago |
| RSI: Overbought | Mar 9, 2026 | 7 months ago |
| RSI: Overbought | Mar 4, 2026 | 8 months ago |
| RSI: Overbought | Feb 25, 2026 | 8 months ago |
| SMA: Bullish | Feb 20, 2026 | 8 months ago |
| SMA: Bullish | Feb 19, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 17, 2026 | 8 months ago |
| SMA: Bearish | Jan 28, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 28, 2026 | 9 months ago |
| SMA: Bullish | Jan 27, 2026 | 9 months ago |
| SMA: Bearish | Jan 26, 2026 | 9 months ago |
| SMA: Bullish | Jan 7, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 7, 2026 | 9 months ago |
| SMA: Bearish | Dec 29, 2025 | 10 months ago |
| SMA: Bearish | Dec 23, 2025 | 10 months ago |
| SMA: Bullish | Dec 22, 2025 | 10 months ago |
| SMA: Bearish | Dec 17, 2025 | 10 months ago |
| SMA: Bearish | Dec 15, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 11, 2025 | 10 months ago |
| SMA: Bearish | Nov 20, 2025 | 11 months ago |
| SMA: Bullish | Nov 19, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 12, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 6, 2025 | 12 months ago |
| SMA: Bearish | Nov 3, 2025 | 12 months ago |
| SMA: Bullish | Oct 31, 2025 | 1 year ago |
Key statistics
- Market cap
- 286.59M
- Enterprise value
- 90.28M
- Trailing P/E
- 0.00
- Forward P/E
- -2.37
- PEG ratio
- 0.00
- Price / sales
- 8.51
- Price / book
- 1.18
- EPS (TTM)
- -1.71
- Beta
- 3.06
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 33.67M
- Revenue growth
- 38.70%
- Free cash flow
- -41.84M
- Total cash
- 255.64M
- Total debt
- 67.09M
- Return on equity
- -46.00%
- Shares outstanding
- 70.59M
- Short % of float
- 13.71%
- 50-day average
- 5.06
- 200-day average
- 5.96
Analyst view
Consensus: buy
Buy
Price target (mean) 15.00 +345.1% upside
Now 3.37
- Target (low)
- 4.00
- Target (mean)
- 15.00
- Target (high)
- 39.00
Ratings (0m) 9 6 buy · 3 hold · 0 sell
- Strong buy1
- Buy5
- Hold3
- Sell0
- Strong sell0
Next earnings
Aug 1, 2024
Expected Aug 1, 2024. Consensus EPS estimate -0.44.
Financials — quick view
CCCC Revenue — quarterly 6.64M
CCCC Net income — quarterly -23.64M
CCCC EPS — quarterly -0.18
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 31, 2024 | Sep 1, 2024 | -0.40 | -0.35 | +0.05 | +12.50% |
| Aug 1, 2024 | Jun 1, 2024 | -0.37 | -0.26 | +0.11 | +29.73% |
| Aug 1, 2024 | Jun 1, 2024 | -0.37 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -0.41 | -0.41 | 0.00 | 0.00% |
| May 8, 2024 | Mar 1, 2024 | -0.41 | — | — | — |
| Feb 22, 2024 | Dec 1, 2023 | -0.67 | -0.68 | -0.01 | -1.49% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | Wells Fargo | up | Equal-Weight | Overweight |
| Nov 18, 2024 | Stephens & Co. | init | — | Equal-Weight |
| Aug 6, 2024 | BMO Capital | reit | Outperform | Outperform |
| May 9, 2024 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| May 9, 2024 | Stifel | main | Buy | Buy |
| Feb 26, 2024 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- c4therapeutics.com
News
- C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
- C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders
- Lake Street Initiates Coverage On C4 Therapeutics with Buy Rating, Announces Price Target of $11
- Tenaya Therapeutics (NASDAQ:TNYA) and C4 Therapeutics (NASDAQ:CCCC) Financial Survey
- Insmed Appoints Two New Directors to Its Board
- Reviewing ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC)
- JP Morgan Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $10
- C4 Therapeutics Presents New Biomarker Data From Phase 1 Clinical Trial Of Cemsidomide In Combination With Dexamethasone In Patients With RRMM At 23rd IMS Annual Meeting
- C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
- Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Your note
Sign in to keep a note on CCCC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS KENDRA | Chief Financial Officer | Conversion of Exercise of derivative security | Nov 6, 2024 | 84,439 |
| ANDERSON KENNETH CARL | Director | Stock Award(Grant) | Sep 30, 2024 | 320,418 |
| BOYLE SCOTT N | Officer | Conversion of Exercise of derivative security | Nov 6, 2024 | 56,567 |
| DUBIN GLENN R. | Director | Stock Award(Grant) | Mar 31, 2024 | 812,682 |
| FISHER STEWART | Officer | Conversion of Exercise of derivative security | Sep 15, 2024 | 130,710 |
| GROGAN DONNA ROY M.D. | Director | Stock Award(Grant) | Sep 30, 2024 | 28,942 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Lynx1 Capital Management Lp | 9.75% | 6,880,527 | 27.93M | Sep 29, 2024 |
| Soleus Capital Management, L.P. | 9.36% | 6,603,996 | 26.81M | Sep 29, 2024 |
| Wasatch Advisors LP | 8.04% | 5,677,368 | 23.05M | Sep 29, 2024 |
| Blackrock Inc. | 6.93% | 4,890,935 | 19.86M | Sep 29, 2024 |
| RA Capital Management, L.P. | 6.91% | 4,878,000 | 19.80M | Sep 29, 2024 |
| Orbimed Advisors LLC. | 6.20% | 4,377,900 | 17.77M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wasatch Ultra Growth Fund | 3.70% | 2,609,942 | 10.60M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 3.03% | 2,135,945 | 8.67M | Sep 29, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.34% | 1,653,493 | 6.71M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.17% | 1,534,793 | 6.23M | Oct 30, 2024 |
| Wasatch Microcap Fund | 1.76% | 1,242,144 | 5.04M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.12% | 789,707 | 3.21M | Sep 29, 2024 |